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found in neurons, ECs, platelets, monocytes, T cells, dendritic cells, and cancer cells. 18 Previous studies showed that Sema7A is involved in the regulation of inflammatory response, cancer progression, and neuron growth. 17, 19, 20 Recently, lung EC Sema7A was reported to be upregulated by HIF-1α (hypoxiainducible factor 1-alpha), an oxygen-sensitive transcription factor, in the setting of acute inflammation induced by hypoxia, lipopolysaccharide, or seawater. [21] [22] [23] However, there has been no report whether Sema7A participates in the development of atherosclerosis.
We have previously shown that disruption of Sema4D, another member of semaphorin family, protects against the development of atherosclerosis. 24 In this study, we used a partial carotid artery ligation (PCL) model in ApoE −/− mice fed with a high-fat diet (HFD) and showed that endothelial Sema7A expression is increased by surgically induced d-flow, whereas genetic deletion of Sema7A ameliorated atherosclerosis in ApoE −/− mice. Sema7A seemed to cause EC dysfunction through endothelial β1 integrin/FAK (focal adhesion kinase)/MEK1/2 (mitogen-activated protein kinase kinase 1/2)/NF-κB (nuclear factor-κB) pathway, acting as a proatherogenic molecule.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Genetic Deletion of Sema7A Reduces Plaque Size in the Aorta of ApoE −/− Mice
To investigate the role of Sema7A in atherosclerosis, we generated Sema7A −/− ApoE −/− mice and fed them the HFD to induce atherosclerosis. After 12 weeks, the mice were euthanized, and their aortas were stained with Sudan IV. Atherosclerotic lesion size was 51.5% smaller in Sema7A − /− ApoE −/− mice than in Sema7A +/+ ApoE −/− mice (5.0±1.0% of the total aorta area versus 10.3±1.1%; P<0.01), and the reduction of the lesion size was most prominent in the aortic arch (59.2%) and less in the descending aorta (41.5%; Figure 1A and 1B). Histological studies showed that areas of lipid accumulation in the aortic root were 51. 8% (Table II in the online-only Data Supplement). In addition, immunostaining also showed high levels of Sema7A protein in human atherosclerotic carotid tissues compared with human healthy abdominal aorta ( Figure 1E ). These results indicate that Sema7A participates in atherosclerosis development.
D-Flow Upregulates Vascular Endothelial Sema7A Expression
Sema7A deletion primarily reduces plaque formation in aortic arch, suggesting a higher expression level of Sema7A in this region. Indeed, higher expression levels of Sema7A mRNA and protein in the aortic arch were observed compared with that in the descending aorta (Figure 2A and 2B) . The lesser curvature of the aorta is an atheroprone region that encounters d-flow compared with the greater curvature ( Figure 2C ). Further studies showed that Sema7A mRNA and protein levels were higher in lesser curvature than in greater curvature ( Figure 2D and 2E). To test whether hemodynamic stress increases Sema7A expression in vivo, we induced d-flow by PCL in wild-type mice 25 ( Figure 2C ; Figure I in the online-only Data Supplement). Compared with the untied right common carotid artery with steady flow (s-flow), left common carotid artery (LCA) showed a 4-fold increase in Sema7A mRNA levels 48 hours after the ligation ( Figure 2F ). To explore the cellular source for the increased Sema7A expression under d-flow, we examined Sema7A protein expression in carotid artery endothelium after the PCL by en face staining. Prominent endothelial Sema7A protein was detected in the ligated LCA, as shown by costaining of Sema7A and CD31 (platelet and endothelial cell adhesion molecule 1), whereas little Sema7A staining was found in the control right common carotid artery ( Figure 2G ). Consistently, Sema7A mRNA level in cultured human umbilical vein endothelial cells (HUVECs) exposed to oscillatory shear stress was significantly higher than that in the cells exposed to laminar shear stress ( Figure 2H ). These data indicate that d-flow upregulates vascular endothelial Sema7A expression.
To understand how d-flow upregulates endothelial Sema7A expression, we performed in a silico promoter analysis and identified potential binding sites in human and mouse Sema7A promoter regions for CREB (cAMP response element-binding protein), a transcription factor known to respond to shear stress 26, 27 ( Figure IIA and IIB in the online-only Data Supplement). Because PKA (protein kinase A) is a canonical CREB upstream regulator in flowmediated signaling, we examined Sema7A expression in HUVECs after inhibiting the PKA-CREB signaling using the PKA inhibitor H89 (N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide·2HCl hydrate). Results showed that H89 reduced CREB phosphorylation and increased Sema7A mRNA and protein expression ( Figure 2I through 2L ). These data suggest that suppression of PKA/CREB signaling may be an underlying mechanism in d-flow-induced endothelial Sema7A expression. Figure 3B , 3C, 3E, and 3F). Leukocyte rolling and adhesion, mediated by selectins and adhesion molecules, are crucial for monocyte recruitment and accumulation in atherogenesis. 29 Given the role of Sema7A in upregulating the expression of ICAM-1 and VCAM-1, as well as P-selectin, we examined the functional relevance of Sema7A in endothelial inflammation. Using a real-time intravital microscopy, we monitored leukocyte rolling and adhesion on mouse cremaster venule endothelium primed by TNF-α (tumor necrosis factor-α). 30 Leukocyte rolling and adhesion were decreased by 45.2% ( 
Sema7A Overexpression Enhances ICAM-1 and VCAM-1 Expression in HUVECs and Monocyte-EC Interaction via β1 Integrin Pathway
To investigate the mechanism by which Sema7A regulates ICAM-1 and VCAM-1 expression and leukocyte adhesion Beta1 integrin is a Sema7A receptor that mediates cellcell interaction in axon outgrowth and T-cell response. 17, 20 Given the presence of β1 integrin in ECs, we hypothesized that Sema7A may mediate endothelial dysfunction through β1 integrin. Flow cytometry showed that β1 integrin blockage by a monoclonal antibody (P5D2) significantly reduced ICAM-1 expression compared with an isotypic control (IgG; Figure 4E ). Similarly, preincubation with a blocking antibody against integrin α1 (5E8D9) subunit reduced ICAM-1 expression in Sema7A-overexpressing HUVECs ( Figure 4E ), suggesting that Sema7A mediates endothelial phenotypic changes, at least in part, through the α1β1 heterodimer.
Previous studies showed that activation of FAK by Sema7A binding to β1 integrin activates downstream MAPK (mitogen-activated protein kinase). 17 NF-κB, the downstream molecule to MAPK, is a canonical switch for the expression of proinflammatory molecules including ICAM-1 and VCAM-1. 31 We analyzed FAK/MAPK/NF-κB signaling in Sema7A-overexpressing HUVECs. As expected, FAK phosphorylation was increased by Sema7A overexpression ( Figure 4F ). Treatment of PF573228 (10 µmol/L), a specific inhibitor for FAK; U0126 (10 µmol/L), a potent inhibitor for both MEK1 and MEK2; or BMS-345541 (20 µmol/L), a highly selective inhibitor for the catalytic subunits of IKK-2 and IKK-1, attenuated ICAM-1 expression in Sema7A-overexpressing HUVECs ( Figure 4G ). Downstream NF-κB P65 phosphorylation was also inhibited by U0126 (10 µmol/L) and BMS-345541 (20 µmol/L; Figure 4H ). These findings indicate that FAK/MEK1/2/NF-κB may act downstream of the Sema7A-integrin β1 axis to mediate vascular endothelial dysfunction. To determine the involvement of β1 integrin and the downstream FAK/MEK1/2/NF-κB signaling in leukocyte-endothelial interaction, an in vitro monocyte-EC adhesion assay was performed. Sema7A-overexpressing HUVECs had a 1.1-fold increase in THP-1 (human acute monocytic leukemia cell line) cell adhesion compared with control HUVECs (60.4±1.8 versus 28.7±0.9 cells/field; P<0.0001). However, the increased monocyte adhesion was attenuated by antibody blockage of integrin β1 or α1 subunits or by inhibition of FAK, MEK1/2, or NF-κB with small-molecule inhibitors ( Figure 4I and 4J) . These results indicate that Sema7A enhances the expression of adhesion molecules and leukocyte adhesion on ECs in a β1 integrin-dependent manner that involves downstream FAK/ MEK1/2/NF-κB signaling. Sema7A is expressed in many cell types. 18 To distinguish the role of vascular versus blood cell-derived Sema7A in leukocyte adhesion, we performed an ex vivo leukocyte adhesion assay, in which aortic endothelium from Sema7A
−/− mice were treated with lipopolysaccharide and incubated with leukocytes from these mice. As shown in Figure 5A, To distinguish the role of vascular versus blood cellderived Sema7A in d-flow-induced atherogenesis in vivo, we generated chimeric mice of which blood cells of Sema7A
ApoE −/− mice were replaced with bone marrow-derived cells from these mice through bone marrow transplantation. A modified PCL was performed 4 weeks after bone marrow transplantation following with HFD for another 2 weeks. As shown in Figure 5B , atherosclerotic lesion size was 
Discussion
In this study, we examined the role of Sema7A, an EC-expressed semaphorin family member, in d-flow-induced vascular inflammatory changes, leukocyte adhesion, and atherosclerotic plaque formation and found that upregulation of Sema7A by d-flow in large arteries contributes to endothelial dysfunction via endothelial integrin β1, whereas deficiency of Sema7A in ApoE −/− mice confers significant protection against atherosclerosis.
Members of semaphorin family are known to promote atherosclerosis by enhancing monocyte-EC adhesion, promoting macrophage retention and neovascularization, [32] [33] [34] although studies indicate that Sema3A expression is reduced in response to proatherogenic conditions. 35 To extend our knowledge on the role of semaphorin family members in atherosclerosis, we measured their expression at distinct aortic regions exposed to d-flow and s-flow. Compared with the descending aorta (s-flow), the aortic arch (d-flow) showed significantly increased Sema7A level but reduced expression of Sema3A, Sema3C, Sema3D, Sema3F, and Sema6A ( Figure VA in the online-only Data Supplement). Given the fact that the causative role of d-flow in atherosclerosis may not be directly estimated because of variations of leukocyte-mediated inflammation, genetic background, and diverse embryonic origin of the aorta in the conventional HFD-fed dyslipidemic mouse model, 36, 37 we used a PCL model that allows a more accurate delineation of d-flow-mediated endothelial dysfunction during atherosclerosis. 25, [38] [39] [40] In this modified model, increased Sema7A expression was found in mouse LCA subjected to PCL compared with the control right common carotid artery, suggesting that Sema7A expression is regulated by d-flow-induced shear stress ( Figure VA and VB in the online-only Data Supplement). Using the atheroscleroticonset mouse model, LDLR −/− mice fed a Western diet for 2 weeks, the expression of more semaphorins have been shown to be affected at sites of altered hemodynamic stress. 35 In this analysis, Sema7A mRNA expression did not show a significant difference between the lesser and greater curvature of the aortic arch; however, whole aorta and not just ECs were analyzed. In addition, it will be interesting to examine whether hyperlipidemic conditions alters Sema7A expression in ECs.
D-flow antagonizes the protective effect of s-flow on blood vessel, leading to chronic inflammation, EC dysfunction, and atherosclerosis. 41, 42 Interestingly, Sema7A is hardly detected in ECs cultured under static or s-flow conditions. In contrast, exposure to d-flow markedly increased Sema7A mRNA and protein levels in the endothelium. To determine how Sema7A transcription is elevated in response to d-flow, we analyzed the Sema7A promoter sequence and identified conserved binding sites (cAMP response elements) for the CREB transcription factor. Activated by s-flow or laminar shear stress, PKA/CREB pathway reduces the expression of proinflammatory genes and maintains endothelial homeostasis. 26 These findings collectively indicate Sema7A as a potential transcriptional target to the shearresponsive transcription factor CREB. This notion is supported by our observation that EC Sema7A expression was increased by H89, an inhibitor of PKA/CREB signaling. Sema7A promoter analysis further indicated the presence of consensus binding sites for other shear-responsive elements, including NF-κB, IRF-1 (interferon regulatory factor 1), and KLF4 (Kruppel-like factor 4), implying that a comprehensive network of transcription factors may be involved in hemodynamic regulation of Sema7A. The regulation of Sema7A by d-flow may also be achieved through epigenetic DNA methylation in its promoter. 40 Future studies are warranted to address the effect of these factors and to provide more mechanistic insights on how Sema7A is regulated under proatherogenic hemodynamics.
Our findings reveal a key role of endothelial Sema7A/β1 integrin axis in d-flow-induced EC dysfunction, inflammation, and atherogenesis. As shown in Figure 5C , first, endothelial Sema7A was upregulated by d-flow, whereas Sema7A deletion attenuated leukocyte adhesion induced by d-flow and atherosclerotic plaque formation in ApoE −/− mice. Second, integrin β1 ligation by Sema7A activates FAK/ MEK1/2/NF-κB signaling in ECs. Third, overexpression of Sema7A in ECs promotes adhesion molecule expression and monocyte-EC interaction. Consistently, Sema7A has been shown to mediate acute inflammation in lung ECs via activating integrin β1. The other known receptor for Sema7A is plexin C1, which has been reported to mediate EC cytoskeleton change and swelling under seawater stimulation. 21 Whether plexin C1 is involved in atherosclerosis remains to be elucidated.
In summary, our data showed a significant role of Sema7A in d-flow-mediated EC dysfunction and atherosclerotic plaque formation. Integrin β1 seems to play a crucial role in mediating the proatherogenic effect of Sema7A that activates a downstream FAK/MAPK/NF-κB pathway, thus promoting leukocyte adhesion and infiltration, and the development of atherosclerosis. These findings suggest new strategies in the prevention and treatments for atherosclerosis.
